NCT Number: NCT02191280
Antistax® in Patients With Chronic Venous Insufficiency
Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II
Looking for future studies?
Notify MeKey information
Age range
25 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female
- Between 25 and 75 years of age
- CVI I or CVI II (without expanded trophic disturbances)
- Willing and able to give written informed consent prior to participation in the study
Exclusion criteria
Concomitant disease(s) exclusion criteria:
- Decompensated cardiac insufficiency
- Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
- Peripheral arterial disease (ankle/arm pressure index < 0.9)
- Current acute phlebitis or thrombosis
- Renal insufficiency (Serum creatinine > 1.5 mg/dl)
- Liver disease (SGPT (ALAT) > 3x upper limit of normal)
- Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
- Anamnestic indications of diabetic microangiopathy or polyneuropathy
- Drug and/or alcohol abuse
- Severe climacteric complaints
- Immobility
- Avalvulia
- Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- State after pulmonary embolism
- Recognized hypersensitivity to the trial drug ingredients
- Current florid venous ulcus
- Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
Previous treatment(s) exclusion criteria:
- Treatment with venous drugs within the last 4 weeks
- Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
- Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
- Changes in post-menopausal Hormone replacement within the last 2 months
Concomitant treatment/non-drug therapy exclusion criteria:
- Other venous drugs apart from the trial medication
- Compression therapy
- Venous surgery at the leg(s)
- Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
- Major surgery requiring full anesthesia
Other exclusion criteria:
- Previously studied under this protocol
- Participation in another clinical trial within the previous 90 days or during the present study
- Patients who have visited a sauna or had other thermal applications in the previous day before any visit
- Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- Patients in a bad general health state according to the investigator's judgment
Treatment and study plan
Antistax®, high dose
DrugPlacebo
DrugPrimary outcomes
-
Changes from baseline of limb volume
Time frame: Baseline, day 84
determined by water displacement
Secondary outcomes
-
Changes of limb volume
Time frame: Baseline, days 42 and 98
determined by water displacement
-
Measurement of calf circumference
Time frame: Baseline, days 42, 84 and 98
in centimeters
-
Measurement of ankle circumference
Time frame: Baseline, days 42, 84 and 98
in centimeters
-
Assessment of subjective symptoms on a visual analogue scale (VAS)
Time frame: Baseline, days 42, 84 and 98
-
Assessment of global efficacy by patient on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
-
Assessment of global efficacy by investigator on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
-
Assessment of global tolerability by patient on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
-
Assessment of global tolerability by investigator on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
-
Number of patients with adverse events
Time frame: up to 14 weeks
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study
Important dates
- Study start
- 1998
- Primary completion
- 1998
- First posted
- Jul 16, 2014
- Registry last updated
- Jul 16, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Isolated Great Saphenous Vein Stripping for Treatment of Varicose Veins in Lower Limbs
NCT07616115
Cardiovascular Diseases, Saphenous Vein
São Paulo, Brazil
View Trial DetailsDigital Supported Compression Bandaging in Patients With Chronic Edema in the Lower Limbs
NCT06438133
Cardiovascular Diseases, Compression; Vein
Bispebjerg, Capital Region, Denmark
View Trial DetailsTransient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)
NCT02061254
Cardiovascular Diseases, Fibrosis
Tours, France
View Trial DetailsThe Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency
NCT01558024
Cardiovascular Diseases, Vascular Diseases
Montpellier, France
View Trial Details